• 141. Ruxolitinib vs triamcinolone - Topical tofacitinib for LPP/FFA - Locus of control in AD - Low-dose naltrexone for LPP/FFA - Alternative/complementary treatments for HSV

  • Sep 30 2024
  • Length: 59 mins
  • Podcast

141. Ruxolitinib vs triamcinolone - Topical tofacitinib for LPP/FFA - Locus of control in AD - Low-dose naltrexone for LPP/FFA - Alternative/complementary treatments for HSV

Listen for free

View show details

  • Summary

  • Ruxolitinib vs triamcinolone -

    Topical tofacitinib for LPP/FFA -

    Locus of control in AD -

    Low-dose naltrexone for LPP/FFA -

    Alternative/complementary treatments for HSV -

    Want to donate to the cause? Do so here!

    Donate to the podcast: uofuhealth.org/dermasphere

    Check out our video content on YouTube:

    www.youtube.com/@dermaspherepodcast

    and VuMedi!: www.vumedi.com/channel/dermasphere/

    The University of Utah's Dermatology

    ECHO: ⁠physicians.utah.edu/echo/dermatology-primarycare -

    ⁠ Connect with us!

    - Web: ⁠dermaspherepodcast.com/⁠ - Twitter: @DermaspherePC

    - Instagram: dermaspherepodcast

    - Facebook: www.facebook.com/DermaspherePodcast/

    - Check out Luke and Michelle’s other podcast,

    SkinCast! ⁠healthcare.utah.edu/dermatology/skincast/⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our

    friends at:

    - ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge)

    - ⁠www.levelex.com/games/top-derm⁠ (A free dermatology game to learn

    more dermatology!
    Show more Show less
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about 141. Ruxolitinib vs triamcinolone - Topical tofacitinib for LPP/FFA - Locus of control in AD - Low-dose naltrexone for LPP/FFA - Alternative/complementary treatments for HSV

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available